87 related articles for article (PubMed ID: 15732779)
21. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
22. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
[TBL] [Abstract][Full Text] [Related]
23. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.
Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC
Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640
[TBL] [Abstract][Full Text] [Related]
24. Placental expression of syndecan 1 is diminished in preeclampsia.
Jokimaa VI; Kujari HP; Ekholm EM; Inki PL; Anttila L
Am J Obstet Gynecol; 2000 Dec; 183(6):1495-8. PubMed ID: 11120517
[TBL] [Abstract][Full Text] [Related]
25. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck.
Inki P; Joensuu H; Grénman R; Klemi P; Jalkanen M
Br J Cancer; 1994 Aug; 70(2):319-23. PubMed ID: 8054282
[TBL] [Abstract][Full Text] [Related]
26. High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery.
Anttonen A; Heikkilä P; Kajanti M; Jalkanen M; Joensuu H
Lung Cancer; 2001 Jun; 32(3):297-305. PubMed ID: 11390011
[TBL] [Abstract][Full Text] [Related]
27. Correlation between reduction of syndecan-1 expression and clinico-pathological parameters in squamous cell carcinoma of tongue.
Ro Y; Muramatsu T; Shima K; Yajima Y; Shibahara T; Noma H; Shimono M
Int J Oral Maxillofac Surg; 2006 Mar; 35(3):252-7. PubMed ID: 16280239
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.
Tsanou E; Ioachim E; Briasoulis E; Charchanti A; Damala K; Karavasilis V; Pavlidis N; Agnantis NJ
J Exp Clin Cancer Res; 2004 Dec; 23(4):641-50. PubMed ID: 15743035
[TBL] [Abstract][Full Text] [Related]
29. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
Baba F; Swartz K; van Buren R; Eickhoff J; Zhang Y; Wolberg W; Friedl A
Breast Cancer Res Treat; 2006 Jul; 98(1):91-8. PubMed ID: 16636895
[TBL] [Abstract][Full Text] [Related]
30. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases.
Roskams T; Rosenbaum J; De Vos R; David G; Desmet V
Hepatology; 1996 Sep; 24(3):524-32. PubMed ID: 8781318
[TBL] [Abstract][Full Text] [Related]
31. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
Kumar-Singh S; Jacobs W; Dhaene K; Weyn B; Bogers J; Weyler J; Van Marck E
J Pathol; 1998 Nov; 186(3):300-5. PubMed ID: 10211120
[TBL] [Abstract][Full Text] [Related]
32. Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations.
Anttonen A; Leppä S; Heikkilä P; Grenman R; Joensuu H
J Cancer Res Clin Oncol; 2006 Jul; 132(7):451-7. PubMed ID: 16557382
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of p27Kip1 expression in Basaloid Squamous Cell Carcinoma of the larynx.
Salerno G; Di Vizio D; Staibano S; Mottola G; Quaremba G; Mascolo M; Galli V; De Rosa G; Insabato L
BMC Cancer; 2006 Jun; 6():146. PubMed ID: 16740156
[TBL] [Abstract][Full Text] [Related]
34. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes.
Inki P; Larjava H; Haapasalmi K; Miettinen HM; Grenman R; Jalkanen M
Eur J Cell Biol; 1994 Feb; 63(1):43-51. PubMed ID: 8005104
[TBL] [Abstract][Full Text] [Related]
35. Angiogenesis and lymphangiogenesis in early-stage laryngeal carcinoma: Prognostic implications.
Bolzoni Villaret A; Barbieri D; Peretti G; Schreiber A; Fisogni S; Lonardi S; Facchetti F; Nicolai P
Head Neck; 2013 Aug; 35(8):1132-7. PubMed ID: 22907864
[TBL] [Abstract][Full Text] [Related]
36. [A study of the relationship between the expression of connexin43, E-cadherin and biological behaviors of human laryngeal cancer].
Sun WH; Liu HM; Li YJ; Ji XR; Liang DP
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 May; 39(5):293-7. PubMed ID: 15338868
[TBL] [Abstract][Full Text] [Related]
37. Syndecan-1 (CD138) expression in acute myeloblastic leukemia cells--an immuno electron microscopic study.
Seftalioglu A; Karakus S; Dundar S; Can B; Erdemli E; Irmak MK; Oztas E; Korkmaz C; Yazar F; Cavusoglu I
Acta Oncol; 2003; 42(1):71-4. PubMed ID: 12665334
[TBL] [Abstract][Full Text] [Related]
38. Syndecan-1 signals independently of beta1 integrins during Raji cell spreading.
Lebakken CS; McQuade KJ; Rapraeger AC
Exp Cell Res; 2000 Sep; 259(2):315-25. PubMed ID: 10964499
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer.
Götte M; Kersting C; Ruggiero M; Tio J; Tulusan AH; Kiesel L; Wülfing P
Anticancer Res; 2006; 26(1B):621-7. PubMed ID: 16739330
[TBL] [Abstract][Full Text] [Related]
40. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY
Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
